RESUMO
We report our experience of 36 renal transplanted patients against a current T negative allo-cross-match, but historical T and/or B positive allo-cross-matches, whatever the result of the current B cross-match. Additionally, we have determined the immunoglobulin class of the antibody directed against B and T lymphocytes. The graft survival rate did not differ between the 36 patients forming the study group, and the 229 patients transplanted within the same period with negative T and B, on current and historical sera, cross-matches. Within this study group there was no changes in graft survival rate for the following three subgroups, which were retrospectively defined: historical positive (14 patients) versus negative (22 patients) T cross-match, current positive (15 patients) versus negative (21 patients) B cross-match, and IgM (16 patients) versus IgG (20 patients) against B lymphocytes. In terms of transplant outcome, our policy was thus safe.
Assuntos
Linfócitos B/imunologia , Transplante de Rim/imunologia , Linfócitos T/imunologia , Adulto , Especificidade de Anticorpos , Soro Antilinfocitário , Feminino , Teste de Histocompatibilidade , Humanos , Imunoglobulina G , Imunoglobulina M , Isoanticorpos , Masculino , Pessoa de Meia-IdadeRESUMO
The effect of recombinant porcine interferon-gamma (rPoIFN gamma) on in vitro production of interleukin 1 (IL-1) by porcine blood monocytes was studied. Three-day-old cultures of porcine adherent blood mononuclear cells were treated by doses of rPoIFN gamma for 3 or 6 days before lipopolysaccharide (LPS)-induction. While rPoIFN gamma alone had no effect, a combined treatment by rPoIFN gamma and LPS enhanced the IL-1 secretory potential of adherent mononuclear cells and, to a lesser extent, the level of cell-associated IL-1. The IL-1 activity was neutralized by anti porcine IL-1 alpha and beta antisera. These results demonstrate that rPoIFN gamma has immunomodulatory effects in vitro on porcine monokine production.
Assuntos
Interferon gama/farmacologia , Interleucina-1/metabolismo , Monócitos/efeitos dos fármacos , Animais , Células Cultivadas , Lipopolissacarídeos/farmacologia , Camundongos , Camundongos Endogâmicos BALB C , Monócitos/metabolismo , Testes de Neutralização , Proteínas Recombinantes , SuínosRESUMO
Most attempts to produce a vaccine against HIV-1 infection are utilizing envelope protein components. Hypothetically such vaccine candidates could stimulate production of antibodies that enhance HIV-1 infection via the macrophage route of entry and, consequently, cannot be detected in the conventional neutralization assay. To study this hypothesis we report an assay designed to evaluate the protective/enhancing activity of serum from seropositive immunized or infected individuals. Highly purified activated FcR-bearing monocytes-macrophages were infected with HIV-1 in the presence of the sera, then washed and cocultured with activated peripheral blood mononuclear cells (PBMC) from a normal donor. Productive viral infection, as evaluated by p24 antigen semiquantitative assay in the culture supernatants, allow evaluation of protective/enhancing activity of the sera. The data clearly show that protective rather than enhancing activity is present in the serum of env protein-immunized individuals.
